belapectin

DRUG3 trials

Sponsors

Galectin Therapeutics Inc.

Conditions

CirrhosisEsophageal Varices in NASH CirrhosisHepatic ImpairmentNASH - Nonalcoholic SteatohepatitisPrevention of Esophageal Varices

Phase 1

GT-032 Belapectin Hepatic Impairment

CompletedNCT04332432

Galectin Therapeutics Inc.Hepatic Impairment

Start: 2020-06-16End: 2022-03-09Updated: 2026-07-14

Phase 2

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

TerminatedNCT04365868

Galectin Therapeutics Inc.Cirrhosis, NASH - Nonalcoholic Steatohepatitis, Prevention of Esophageal Varices

Start: 2020-06-25End: 2025-04-10Updated: 2026-06-30

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis.

CompletedCTIS2024-512619-28-00

Galectin Therapeutics Inc.Esophageal Varices in NASH Cirrhosis

Start: 2021-03-08End: 2025-02-18Target: 28Updated: 2025-01-30

Related Papers

Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.

2026-05-01

Enhancing Histology Detection in <scp>MASH</scp> Cirrhosis for Artificial Intelligence Pathology Platform by Expert Pathologist Training

Liver international communications.2024-12-012 citations

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Journal for ImmunoTherapy of Cancer2021-04-0192 citations